Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics
- 4 June 2008
- journal article
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 2 (6), 721-729
- https://doi.org/10.1517/17530059.2.6.721
Abstract
Background: Developments in genomics and biotechnology provide unprecedented opportunities for the development of effective therapeutics and companion diagnostics for matching the right drug to the right patient. Effective co-development involves many new challenges with increased opportunity for success as well as delay and failure. Objective: Clinical trial designs and adaptive analysis plans for the prospective design of pivotal trials of new therapeutics and companion diagnostics are reviewed. Conclusions: Effective co-development requires careful prospective planning of the design and analysis strategy for pivotal clinical trials. Randomized clinical trials continue to be important for evaluating the effectiveness of new treatments, but the target populations for analysis should be prospectively specified based on the companion diagnostic. Post hoc analyses of traditionally designed randomized clinical trials are often deeply problematic. Clear separation is generally required of the data used for de...Keywords
This publication has 30 references indexed in Scilit:
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized TrialsJNCI Journal of the National Cancer Institute, 2008
- Anthracyclines in the Treatment of HER2 -Negative Breast CancerJNCI Journal of the National Cancer Institute, 2008
- HER2 and Response to Paclitaxel in Node-Positive Breast CancerNew England Journal of Medicine, 2007
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With CetuximabJournal of Clinical Oncology, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsThe Oncologist, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Clinical Application of cDNA Microarrays in OncologyThe Oncologist, 2003
- Improving the evaluation of new cancer treatments: challenges and opportunitiesNature Reviews Cancer, 2003
- Statistical aspects of prognostic factor studies in oncologyBritish Journal of Cancer, 1994